1800-272-662
Shopping Cart 0
countryflagAU
Login

Hikma Pharmaceuticals PLC

Healthcare GB HIK

1214.0GBX
17.00(1.42%)

Last update at 2026-03-11T13:48:00Z

Day Range

1200.001230.00
LowHigh

52 Week Range

1492.412222.00
LowHigh

Fundamentals

  • Previous Close 1197.00
  • Market Cap3919.75M
  • Volume444826
  • P/E Ratio33.45
  • Dividend Yield2.79%
  • EBITDA823.00M
  • Revenue TTM2731.00M
  • Revenue Per Share TTM12.36
  • Gross Profit TTM 1265.00M
  • Diluted EPS TTM0.53

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 233.00M 544.00M 558.00M 491.00M 293.00M
Minority interest -3.00000M 1.00M 13.00M 12.00M 12.00M
Net income 188.00M 421.00M 431.00M 486.00M 282.00M
Selling general administrative 509.00M 488.00M 464.00M 494.00M 246.00M
Selling and marketing expenses - - - 494.00M 224.00M
Gross profit 1238.00M 1301.00M 1201.00M 1148.00M 1050.00M
Reconciled depreciation 372.00M 145.00M 91.00M 99.00M 121.00M
Ebit 507.00M 582.00M 579.00M 493.00M 331.00M
Ebitda 700.00M 735.00M 652.00M 659.00M 452.00M
Depreciation and amortization 193.00M 153.00M 73.00M 166.00M 121.00M
Non operating income net other - - - - -
Operating income 507.00M 582.00M 579.00M 493.00M 378.00M
Other operating expenses 2035.00M 1994.00M 1827.00M 1714.00M 1692.00M
Interest expense 77.00M 69.00M 69.00M 67.00M 41.00M
Tax provision 42.00M 124.00M 128.00M 4.00M 8.00M
Interest income 3.00M 30.00M 47.00M 6.00M 3.00M
Net interest income -52.00000M -39.00000M -22.00000M -1.00000M -77.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 42.00M 124.00M 128.00M 4.00M 8.00M
Total revenue 2517.00M 2553.00M 2341.00M 2207.00M 2070.00M
Total operating expenses 756.00M 742.00M 687.00M 655.00M 672.00M
Cost of revenue 1279.00M 1252.00M 1140.00M 1059.00M 1020.00M
Total other income expense net -274.00000M -38.00000M -21.00000M -2.00000M -85.00000M
Discontinued operations - - - - -
Net income from continuing ops 191.00M 420.00M 430.00M 487.00M 285.00M
Net income applicable to common shares 188.00M 421.00M 431.00M 486.00M 282.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets - 4471.00M 4372.00M 4135.00M 3930.00M
Intangible assets - 735.00M 607.00M 587.00M 552.00M
Earning assets - - - - -
Other current assets - 110.00M 97.00M 46.00M 39.00M
Total liab - 2323.00M 1905.00M 1987.00M 1801.00M
Total stockholder equity - 2135.00M 2453.00M 2135.00M 2117.00M
Deferred long term liab - - - - -
Other current liab - 638.00M 339.00M 290.00M 315.00M
Common stock - 40.00M 42.00M 41.00M 41.00M
Capital stock - 40.00M 42.00M 41.00M 41.00M
Retained earnings - 2092.00M 2189.00M 1892.00M 1973.00M
Other liab - 111.00M 164.00M 195.00M 223.00M
Good will - 389.00M 285.00M 289.00M 282.00M
Other assets - 215.00M 230.00M 235.00M 257.00M
Cash - 270.00M 426.00M 323.00M 442.00M
Cash and equivalents - - - - -
Total current liabilities - 1077.00M 1016.00M 1028.00M 1471.00M
Current deferred revenue - - 294.00M 100.00M 105.00M
Net debt - 1013.00M 420.00M 609.00M 243.00M
Short term debt - 148.00M 121.00M 168.00M 578.00M
Short long term debt - 139.00M 112.00M 158.00M 569.00M
Short long term debt total - 1283.00M 846.00M 932.00M 685.00M
Other stockholder equity - 3.00M 222.00M 202.00M 103.00M
Property plant equipment - 1081.00M 1146.00M 1068.00M 962.00M
Total current assets - 1999.00M 2094.00M 1922.00M 1848.00M
Long term investments - - - - 43.00M
Net tangible assets - 1011.00M 1561.00M 1259.00M 1283.00M
Short term investments - 22.00M 24.00M 24.00M 23.00M
Net receivables - 843.00M 876.00M 796.00M 799.00M
Long term debt - 1074.00M 651.00M 692.00M 48.00M
Inventory - 776.00M 695.00M 757.00M 568.00M
Accounts payable - 291.00M 262.00M 470.00M 473.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -728.00000M
Additional paid in capital - - - - -
Common stock total equity - - - 41.00M 41.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -1.00000M
Accumulated amortization - - - - -
Non currrent assets other - 22.00M 24.00M 24.00M 23.00M
Deferred long term asset charges - - - - -
Non current assets total - 2472.00M 2278.00M 2213.00M 2082.00M
Capital lease obligations - 70.00M 83.00M 82.00M 68.00M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -607.00000M -238.00000M -3.00000M 8.00M -4.00000M
Change to liabilities 16.00M 14.00M 6.00M -6.00000M 88.00M
Total cashflows from investing activities -607.00000M -238.00000M -283.00000M -151.00000M -96.00000M
Net borrowings 447.00M -114.00000M 220.00M -10.00000M -141.00000M
Total cash from financing activities -58.00000M -287.00000M -298.00000M -155.00000M -278.00000M
Change to operating activities -49.00000M 84.00M 13.00M -34.00000M -21.00000M
Net income 233.00M 544.00M 558.00M 491.00M 282.00M
Change in cash -156.00000M 103.00M -119.00000M 166.00M 49.00M
Begin period cash flow 426.00M 323.00M 442.00M 276.00M 227.00M
End period cash flow 270.00M 426.00M 323.00M 442.00M 276.00M
Total cash from operating activities 530.00M 638.00M 464.00M 472.00M 430.00M
Issuance of capital stock - - - - -
Depreciation 193.00M 145.00M 91.00M 99.00M 121.00M
Other cashflows from investing activities -3.00000M -12.00000M -56.00000M 33.00M 48.00M
Dividends paid 125.00M 120.00M 109.00M 97.00M 84.00M
Change to inventory -102.00000M 38.00M -180.00000M -25.00000M -51.00000M
Change to account receivables 4.00M -166.00000M -47.00000M 21.00M -41.00000M
Sale purchase of stock -300.00000M - -375.00000M - -
Other cashflows from financing activities 1692.00M 309.00M -1.00000M 226.00M 178.00M
Change to netincome 283.00M 66.00M 105.00M -87.00000M 64.00M
Capital expenditures 225.00M 229.00M 224.00M 186.00M 139.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -131.00000M -30.00000M -208.00000M -44.00000M -25.00000M
Stock based compensation 22.00M 29.00M 27.00M 24.00M 21.00M
Other non cash items 213.00M 39.00M 22.00M 1.00M 31.00M
Free cash flow 305.00M 409.00M 240.00M 286.00M 291.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HIK
Hikma Pharmaceuticals PLC		 17.00 1.42% 1214.00 33.45 11.14 1.45 2.32 1.76 8.98
HLN
Haleon PLC		 -4.3 1.15% 368.70 24.73 16.86 2.63 1.81 3.17 16.57
HCM
HUTCHMED China Ltd		 1.00 0.47% 215.00 - - 3.22 3.97 2.39 -19.4252
AGY
Allergy Therapeutics		 -0.15 1.30% 11.35 - 106.38 12.27 83.28 13.92 -4.1496
ANCR
Animalcare Group Plc		 -1.0 0.37% 266.00 67.50 20.28 2.30 1.71 2.52 17.14

Reports Covered

Stock Research & News

View All

Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.

Hikma Pharmaceuticals PLC

1 New Burlington Place, London, United Kingdom, W1S 2HR

Key Executives

Name Title Year Born
Engineer Said Samih Taleb Darwazah Exec. Chairman & CEO 1957
Mr. Mazen Samih Taleb Darwazah Exec. Vice Chairman & Pres of MENA 1958
Mr. Khalid Waleed Hosny Al Nabilsi Chief Financial Officer 1972
Mr. Hussein Arkhagha Company Sec. & Chief Counsel NA
Mr. Bassam Wael Rushdi Kanaan CFA, CPA Exec. VP of Corp. Devel. and M&A 1965
Ms. Susan Ringdal Exec. VP of Strategic Planning & Global Affairs NA
Ms. Majda Labadi Exec. VP of Organisational Devel. NA
Mr. Riad Mishlawi Pres of Injectables NA
Mr. Brian Hoffmann Pres of Generics NA
Mr. Samuel Park Global Head of Intellectual Property (IP) & Gen. Counsel for US NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.